Opus Genetics Inc. (IRD)
NASDAQ: IRD
· Real-Time Price · USD
0.93
-0.01 (-1.20%)
At close: Jun 17, 2025, 3:59 PM
0.94
1.04%
After-hours: Jun 17, 2025, 05:49 PM EDT
-1.20% (1D)
| Bid | 0.92 |
| Market Cap | 55.5M |
| Revenue (ttm) | 10.99M |
| Net Income (ttm) | -57.53M |
| EPS (ttm) | -2.1 |
| PE Ratio (ttm) | -0.44 |
| Forward PE | -1.77 |
| Analyst | Buy |
| Ask | 0.95 |
| Volume | 281,379 |
| Avg. Volume (20D) | 923,926 |
| Open | 0.92 |
| Previous Close | 0.94 |
| Day's Range | 0.92 - 0.97 |
| 52-Week Range | 0.65 - 2.18 |
| Beta | 0.29 |
Analyst Forecast
According to 0 analyst ratings, the average rating for IRD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
+9.6%
Opus Genetics shares are trading higher after the ...
Unlock content with
Pro Subscription
6 months ago
+18.93%
Opus Genetics shares are trading higher after the company announced it secured an FDA agreement under special protocol assessment for its Phase 3 trial of Oral APX3330 in diabetic retinopathy.
